97 related articles for article (PubMed ID: 11717806)
1. DPC-083. DuPont Pharmaceuticals.
Lim ML
Curr Opin Investig Drugs; 2001 Sep; 2(9):1209-12. PubMed ID: 11717806
[TBL] [Abstract][Full Text] [Related]
2. The effect of NNRTIs on HIV reverse transcriptase dimerization.
Tachedjian G; Goff SP
Curr Opin Investig Drugs; 2003 Aug; 4(8):966-73. PubMed ID: 14508881
[TBL] [Abstract][Full Text] [Related]
3. Discovery of second generation quinazolinone non-nucleoside reverse transcriptase inhibitors of HIV-1.
Corbett JW; Rodgers JD
Prog Med Chem; 2002; 40():63-105. PubMed ID: 12516523
[TBL] [Abstract][Full Text] [Related]
4. Non-nucleoside reverse transcriptase inhibitors (NNRTIs): past, present, and future.
De Clercq E
Chem Biodivers; 2004 Jan; 1(1):44-64. PubMed ID: 17191775
[TBL] [Abstract][Full Text] [Related]
5. Novel 8-substituted dipyridodiazepinone inhibitors with a broad-spectrum of activity against HIV-1 strains resistant to non-nucleoside reverse transcriptase inhibitors.
O'Meara JA; Yoakim C; Bonneau PR; Bös M; Cordingley MG; Déziel R; Doyon L; Duan J; Garneau M; Guse I; Landry S; Malenfant E; Naud J; Ogilvie WW; Thavonekham B; Simoneau B
J Med Chem; 2005 Aug; 48(17):5580-8. PubMed ID: 16107158
[TBL] [Abstract][Full Text] [Related]
6. In vitro characterization of a simian immunodeficiency virus-human immunodeficiency virus (HIV) chimera expressing HIV type 1 reverse transcriptase to study antiviral resistance in pigtail macaques.
Ambrose Z; Boltz V; Palmer S; Coffin JM; Hughes SH; Kewalramani VN
J Virol; 2004 Dec; 78(24):13553-61. PubMed ID: 15564466
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors.
Corbett JW; Ko SS; Rodgers JD; Gearhart LA; Magnus NA; Bacheler LT; Diamond S; Jeffrey S; Klabe RM; Cordova BC; Garber S; Logue K; Trainor GL; Anderson PS; Erickson-Viitanen SK
J Med Chem; 2000 May; 43(10):2019-30. PubMed ID: 10821714
[TBL] [Abstract][Full Text] [Related]
8. The design and synthesis of diaryl ether second generation HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) with enhanced potency versus key clinical mutations.
Tucker TJ; Saggar S; Sisko JT; Tynebor RM; Williams TM; Felock PJ; Flynn JA; Lai MT; Liang Y; McGaughey G; Liu M; Miller M; Moyer G; Munshi V; Perlow-Poehnelt R; Prasad S; Sanchez R; Torrent M; Vacca JP; Wan BL; Yan Y
Bioorg Med Chem Lett; 2008 May; 18(9):2959-66. PubMed ID: 18396399
[TBL] [Abstract][Full Text] [Related]
9. Fosamprenavir. Vertex Pharmaceuticals/GlaxoSmithKline.
Corbett AH; Kashuba AD
Curr Opin Investig Drugs; 2002 Mar; 3(3):384-90. PubMed ID: 12054084
[TBL] [Abstract][Full Text] [Related]
10. Novel treatment options for pediatric HIV infection.
Day E; Buckberry K; Sharland MR; Chakraborty R
Curr Opin Investig Drugs; 2008 Feb; 9(2):170-5. PubMed ID: 18246519
[TBL] [Abstract][Full Text] [Related]
11. New anti-HIV agents and targets.
De Clercq E
Med Res Rev; 2002 Nov; 22(6):531-65. PubMed ID: 12369088
[TBL] [Abstract][Full Text] [Related]
12. Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1.
Chan JH; Freeman GA; Tidwell JH; Romines KR; Schaller LT; Cowan JR; Gonzales SS; Lowell GS; Andrews CW; Reynolds DJ; St Clair M; Hazen RJ; Ferris RG; Creech KL; Roberts GB; Short SA; Weaver K; Koszalka GW; Boone LR
J Med Chem; 2004 Feb; 47(5):1175-82. PubMed ID: 14971897
[TBL] [Abstract][Full Text] [Related]
13. New nonnucleoside reverse transcriptase inhibitors.
GMHC Treat Issues; 1999 Feb; 13(2):10. PubMed ID: 11366114
[TBL] [Abstract][Full Text] [Related]
14. SPD-754. Shire.
Zhu M
Curr Opin Investig Drugs; 2003 Aug; 4(8):1004-9. PubMed ID: 14508885
[TBL] [Abstract][Full Text] [Related]
15. Structure-based design, parallel synthesis, structure-activity relationship, and molecular modeling studies of thiocarbamates, new potent non-nucleoside HIV-1 reverse transcriptase inhibitor isosteres of phenethylthiazolylthiourea derivatives.
Ranise A; Spallarossa A; Cesarini S; Bondavalli F; Schenone S; Bruno O; Menozzi G; Fossa P; Mosti L; La Colla M; Sanna G; Murreddu M; Collu G; Busonera B; Marongiu ME; Pani A; La Colla P; Loddo R
J Med Chem; 2005 Jun; 48(11):3858-73. PubMed ID: 15916438
[TBL] [Abstract][Full Text] [Related]
16. Revisiting the concept of a genetic barrier to resistance.
Rusconi S
J HIV Ther; 2006 Dec; 11(4):81-3. PubMed ID: 17578211
[No Abstract] [Full Text] [Related]
17. Dawn of non-nucleoside inhibitor-based anti-HIV microbicides.
D'Cruz OJ; Uckun FM
J Antimicrob Chemother; 2006 Mar; 57(3):411-23. PubMed ID: 16431862
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and evaluation of N-aryl pyrrolidinones as novel anti-HIV-1 agents. Part 1.
Wu B; Kuhen K; Ngoc Nguyen T; Ellis D; Anaclerio B; He X; Yang K; Karanewsky D; Yin H; Wolff K; Bieza K; Caldwell J; He Y
Bioorg Med Chem Lett; 2006 Jul; 16(13):3430-3. PubMed ID: 16632349
[TBL] [Abstract][Full Text] [Related]
19. Non-nucleoside reverse transcriptase inhibitors (NNRTIs) for the treatment of human immunodeficiency virus type 1 (HIV-1) infections: strategies to overcome drug resistance development.
de Clercq E
Med Res Rev; 1996 Mar; 16(2):125-57. PubMed ID: 8656777
[No Abstract] [Full Text] [Related]
20. [Approval of a new nucleoside. Component of complete once daily regimen].
MMW Fortschr Med; 2004 Apr; 146 Spec No 1():91. PubMed ID: 15373067
[No Abstract] [Full Text] [Related]
[Next] [New Search]
